Federal Register / Vol. 62, No. 43 / Wednesday, March 5, 1997 / Notices 10063

National Institutes of Health

Advertisement of an Opportunity To

Investigate the Effect of Nitroxide

Compounds on Diseases Relating to

Stresses of Aging

AGENCY: National Institute on Aging,

NIH.

ACTION: Advertisement of an

opportunity.

SUMMARY: The National Institute on

Aging is seeking a Cooperative Research

and Development Agreement (CRADA)

with a pharmaceutical company to

investigate the effect of nitroxide

compounds on diseases related to the

stresses of aging.

The Collaborator must be able to

collaborate with NIA staff to explore the

effect nitroxides have on diseases of

aging. The Collaborator must have a

demonstrated record of success in

privately producing nitroxide

compounds suitable for pharmaceutical

application, as well as a reputation for

excellence in research.

The term of the CRADA will be up to

five (5) years.

DATES: Interested parties should notify

this office in writing of their intent to

file a formal proposal no later than May

5, 1997. Formal proposals must be

submitted to this office no later than

June 3, 1997.

ADDRESSES: Inquiries and proposals

regarding this opportunity should be

addressed to Bruce D. Goldstein, J.D.,

(Tel. #301–496–0477, FAX # 301–402–

2177), Office of Technology

Development, National Center Institute,

Executive Plaza South, Suite 450, 6120

Executive Blvd. MSC 7182, Bethesda,

Maryland, 20892.

SUPPLEMENTARY INFORMATION: A CRADA

is the anticipated joint agreement to be

entered into by NIA pursuant to the

Federal Technology Transfer Act of

1986, as amended by the National

Technology Transfer Act (Pub. L. #104–

1993 (1996)) and by Executive Order

12591 of October 10, 1987. NIA is

presently exploring the protective

effects of nitroxide compounds on

oxyradical-induced oxidative stress, to

the extent such stresses are related to

diseases of aging.

• Under the present proposal, the

goal of the CRADA will be research into,

and development of, the following

technology:

• Assessment of the qualitative and

quantitative influence nitroxide

compounds have on various aspects of

the aging process.

• Development of new nitroxide

compounds having in vivo inhibitive

effect on the formation of oxyradicals.

• Development of new nitroxide

compounds that enhance neuronal

function and performance of aged

animals.

Party Contributions

The role of NIA includes the

following:

(1) Provide staff, expertise, &

materials for the development of the

desired compounds;

(2) Evaluate the work product of

Collaborator to ensure progress toward

meeting the CRADA goals; and

(3) Provide work space, expertise, and

equipment for production of any

prototypes developed.

The role of the successful Collaborator

will include the following:

(1) Provide expertise on biological

aging mechanisms and assistance in the

development of nitroxide compounds

likely to have therapeutic value;

(2) Provide funding, as necessary, in

support of production and

dissemination of the desired

compounds; and

(3) Provide resources and expertise to

market any products developed.

Selection Criteria

Proposals submitted for consideration

should fully address each of the

following qualifications:

(1) Expertise:

(A) Demonstrated expertise in

developing and producing nitroxide

compounds;

B. Demonstrated expertise on

biological aging mechanisms;

C. Demonstrated ability to secure

national and international marketing

and distribution of nitroxide

compounds;

D. Demonstrated expertise in

overseeing all aspects of product

development; and

E. Demonstrated intellectual ability to

participate in the research and

commercial ability to guide

development of the results into a viable

product line.

(2) Physical Resources:

A. An established headquarters with

offices, space, and equipment;

B. Access to the organization during

business hours by telephone, mail, email, the Internet, and other evolving

technologies; and

C. Sufficient financial resources to

support the current activities of the

CRADA to meet the needs of NIA.

Dated: February 18, 1997.

Thomas D. Mays,

Director, Office of Technology Development,

NCI, NIH.

[FR Doc. 97–5322 Filed 3–4–97; 8:45 am]

BILLING CODE 4140–01–M

National Cancer Institute; Notice of

Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following meeting

of the National Cancer Institute Initial

Review Group:

Agenda/Purpose: To review and evaluate

grant applications.

Committee Name: Subcommittee D—

Clinical Research Studies Subcommittee.

Date: April 1–2, 1997.

Time: 8:00 am.

Place: DoubleTree Hotel, 1750 Rockville

Pike, Rockville, MD 20852.

Contact Person: Martin H. Goldrosen, Ph.D,

Scientific Review Administrator, National

Cancer Institute, NIH, 6130 Executive Blvd.

Room 635C, Bethesda, Md 20892, Telephone:

301–496–7930.

The meeting will be closed in accordance

with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Program Numbers: 93.393, Cancer Cause and

Prevention Research; 93.394, Cancer

Detection and Diagnosis Research. 93.395,

Cancer Treatment Research; 93.396, Cancer

Biology Research; 93.397, Cancer Centers

Support; 93.398, Cancer Research Manpower;

93.399, Cancer Control)

Dated: February 27, 1997.

LaVerne Y. Springfield,

Committee Management Officer, NIH.

[FR Doc. 97–5319 Filed 3–4–97; 8:45 am]

BILLING CODE 4140–01–M

National Cancer Institute; Notice of

Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

National Cancer Institute Special

Emphasis Panel (SEP) meeting:

Name of SEP: Investigator Grants for

Clinical Center Therapy Research.

Date: March 24–26, 1997.

Time: 9:00 am.

Place: DoubleTree Hotel, Halpine Room,

1750 Rockville Pike, Rockville, MD 20852.

Contact Person: Wilna A. Woods, Ph.D.,

Scientific Review Administrator, National

Cancer Institute, NIH, Executive Plaza North,

Room 605, 6130 Executive Boulevard, MSC

7410, Bethesda, MD 20892–7405, Telephone:

301/496–7903.

Purpose/Agenda: To evaluate and review

grant applications.

The meeting will be closed in accordance

with the provisions set forth in secs.